Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2021 | Radioimmunotherapy | Original Article

FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of ¹⁷⁷Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma

Authors: Ayca Løndalen, Johan Blakkisrud, Mona-Elisabeth Revheim, Ulf Erik Madsbu, Jostein Dahle, Arne Kolstad, Caroline Stokke

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2021

Abstract

Purpose

¹⁷⁷Lu-lilotomab satetraxetan targets the CD37 antigen and has been investigated in a first-in-human phase 1/2a study for relapsed non-Hodgkin lymphoma (NHL). Tumor dosimetry and response evaluation can be challenging after radioimmunotherapy (RIT). Changes in FDG PET/CT parameters after RIT and correlations with tumor-absorbed doses has not been examined previously in patients with lymphoma. Treatment-induced changes were measured at FDG PET/CT and ceCT to evaluate response at the lesion level after treatment, and correlations with tumor-absorbed doses were investigated.

Methods

Forty-five tumors in 16 patients, with different pre-treatment and pre-dosing regimens, were included. Dosimetry was performed based on multiple SPECT/CT images. FDG PET/CT was performed at baseline and at 3 and 6 months. SUV_max, MTV, TLG, and changes in these parameters were calculated for each tumor. Lesion response was evaluated at 3 and 6 months (PET_3months and PET_6months) based on Deauville criteria. Anatomical changes based on ceCT at baseline and at 6 and 12 months were investigated by the sum of perpendiculars (SPD).

Results

Tumor-absorbed doses ranged from 35 to 859 cGy. Intra- and interpatient variations were observed. Mean decreases in PET parameters from baseline to 3 months were ΔSUV_max-3months 61%, ΔMTV_3months 80%, and ΔTLG_3months 77%. There was no overall correlation between tumor-absorbed dose and change in FDG PET or ceCT parameters at the lesion level or significant difference in tumor-absorbed doses between metabolic responders and non-responders after treatment.

Conclusion

Our analysis does not show any correlation between tumor-absorbed doses and changes in FDG PET or ceCT parameters for the included lesions. The combination regimen, including cold antibodies, may be one of the factors precluding such a correlation. Increased intra-patient response with increased tumor-absorbed doses was observed for most patients, implying individual variations in radiation sensitivity or biology.

Trial registration

ClinicalTrials.gov Identifier (NCT01796171). Registered December 2012

Available only for authorised users

Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92. https://doi.org/10.1016/j.radonc.2011.05.013.CrossRefPubMed

Pouget JP, Lozza C, Deshayes E, Boudousq V, Navarro-Teulon I. Introduction to radiobiology of targeted radionuclide therapy. Front Med (Lausanne). 2015;2:12. https://doi.org/10.3389/fmed.2015.00012.CrossRef

Pouget JP, Navarro-Teulon I, Bardies M, Chouin N, Cartron G, Pelegrin A, et al. Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol. 2011;8(12):720–34. https://doi.org/10.1038/nrclinonc.2011.160.CrossRefPubMed

Koral KF, Dewaraja Y, Li J, Lin Q, Regan DD, Zasadny KR, et al. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med. 2003;44(3):457–64.PubMed

Sgouros G, Squeri S, Ballangrud AM, Kolbert KS, Teitcher JB, Panageas KS, et al. Patient-specific, 3-dimensional dosimetry in non-Hodgkin’s lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med. 2003;44(2):260–8.PubMed

Dewaraja YK, Schipper MJ, Roberson PL, Wilderman SJ, Amro H, Regan DD, et al. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med. 2010;51(7):1155–62. https://doi.org/10.2967/jnumed.110.075176.CrossRefPubMed

Dewaraja YK, Schipper MJ, Shen J, Smith LB, Murgic J, Savas H, et al. Tumor-absorbed dose predicts progression-free survival following (131)I-tositumomab radioimmunotherapy. J Nucl Med. 2014;55(7):1047–53. https://doi.org/10.2967/jnumed.113.136044.CrossRefPubMed

Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352(5):441–9. https://doi.org/10.1056/NEJMoa041511.CrossRefPubMed

Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007;48(11):1767–76. https://doi.org/10.2967/jnumed.107.043489.CrossRefPubMed

10.

Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, et al. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin’s lymphoma. Anticancer Res. 2013;33(1):85–95.PubMed

11.

Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, et al. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2020;4(17):4091–101. https://doi.org/10.1182/bloodadvances.2020002583.CrossRefPubMedPubMedCentral

12.

Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood. 2007;110(7):2569–77. https://doi.org/10.1182/blood-2006-12-062927.CrossRefPubMedPubMedCentral

13.

Schwartz-Albiez R, Dorken B, Hofmann W, Moldenhauer G. The B Cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol. 1988;140(3):905–14.PubMed

14.

Bertoni F, Stathis A. Staining the target: CD37 expression in lymphomas. Blood. 2016;128(26):3022–3. https://doi.org/10.1182/blood-2016-11-748137.CrossRefPubMed

15.

Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14(7):1974–81. https://doi.org/10.1200/JCO.1996.14.7.1974.CrossRefPubMed

16.

Heider KH, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E, et al. A novel fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood. 2011;118(15):4159–68. https://doi.org/10.1182/blood-2011-04-351932.CrossRefPubMedPubMedCentral

17.

Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC, et al. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood. 2013;122(20):3500–10. https://doi.org/10.1182/blood-2013-05-505685.CrossRefPubMed

18.

Repetto-Llamazares AHV, Malenge MM, O'Shea A, Eiriksdottir B, Stokke T, Larsen RH, et al. Combination of (177) Lu-lilotomab with rituximab significantly improves the therapeutic outcome in pre-clinical models of non-Hodgkin’s lymphoma. Eur J Haematol. 2018. https://doi.org/10.1111/ejh.13139.

19.

Blakkisrud J, Londalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T, et al. Tumor-absorbed dose for non-Hodgkin lymphoma patients treated with the anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan. J Nucl. 2017;58(1):48–54. https://doi.org/10.2967/jnumed.116.173922.CrossRef

20.

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54. https://doi.org/10.1007/s00259-014-2961-x.CrossRefPubMed

21.

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S. https://doi.org/10.2967/jnumed.108.057307.CrossRefPubMed

22.

Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257–60. https://doi.org/10.1080/10428190903040048.CrossRefPubMed

23.

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68. https://doi.org/10.1200/JCO.2013.54.8800.CrossRefPubMedPubMedCentral

24.

Barzenje DA, Cvancarova Smastuen M, Liestol K, Fossa A, Delabie J, Kolstad A, et al. Radiotherapy compared to other strategies in the treatment of stage I/II follicular lymphoma: a study of 404 patients with a median follow-up of 15 years. PLoS One. 2015;10(7):e0131158. https://doi.org/10.1371/journal.pone.0131158.CrossRefPubMedPubMedCentral

25.

Haas RL. Low dose radiotherapy in indolent lymphomas, enough is enough. Hematol Oncol. 2009;27(2):71–81. https://doi.org/10.1002/hon.882.CrossRefPubMed

26.

Wang YV, Leblanc M, Wade M, Jochemsen AG, Wahl GM. Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell. 2009;16(1):33–43. https://doi.org/10.1016/j.ccr.2009.05.008.CrossRefPubMedPubMedCentral

27.

Nowarski R, Wilner OI, Cheshin O, Shahar OD, Kenig E, Baraz L, et al. APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair. Blood. 2012;120(2):366–75. https://doi.org/10.1182/blood-2012-01-402123.CrossRefPubMedPubMedCentral

28.

Li Q, Xu X, Zhong W, Du Q, Yu B, Xiong H. IL-17 induces radiation resistance of B lymphoma cells by suppressing p53 expression and thereby inhibiting irradiation-triggered apoptosis. Cell Mol Immunol. 2015;12(3):366–72. https://doi.org/10.1038/cmi.2014.122.CrossRefPubMed

29.

O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt’s lymphoma cell lines. Cancer Res. 1993;53(20):4776–80.PubMed

30.

Zand H, Rahimipour A, Salimi S, Shafiee SM. Docosahexaenoic acid sensitizes Ramos cells to gamma-irradiation-induced apoptosis through involvement of PPAR-gamma activation and NF-kappaB suppression. Mol Cell Biochem. 2008;317(1–2):113–20. https://doi.org/10.1007/s11010-008-9838-x.CrossRefPubMed

31.

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86. https://doi.org/10.1200/JCO.2006.09.2403.CrossRefPubMed

32.

Moghbel MC, Mittra E, Gallamini A, Niederkohr R, Chen DL, Zukotynski K, et al. Response assessment criteria and their applications in lymphoma: part 2. J Nucl Med. 2017;58(1):13–22. https://doi.org/10.2967/jnumed.116.184242.CrossRefPubMed

33.

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32(27):3048–58. https://doi.org/10.1200/JCO.2013.53.5229.CrossRefPubMedPubMedCentral

34.

Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29(23):3194–200. https://doi.org/10.1200/JCO.2011.35.0736.CrossRefPubMed

35.

Fan Y, Zhang Y, Yang Z, Ying Z, Zhou N, Liu C, et al. Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUVmax-liver-based interpretation for predicting the outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2017;58(9):1–9. https://doi.org/10.1080/10428194.2016.1277384.CrossRefPubMed

36.

Zhang Y, Fan Y, Ying Z, Song Y, Zhu J, Yang Z, et al. Can the SUVmax-liver-based interpretation improve prognostic accuracy of interim and posttreatment (18)F-FDG PET/CT in patients with diffuse large B-cell lymphoma? Leuk Lymphoma. 2018;59(3):660–9. https://doi.org/10.1080/10428194.2017.1357171.CrossRefPubMed

37.

Jacene HA, Filice R, Kasecamp W, Wahl RL. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med. 2009;50(1):8–17. https://doi.org/10.2967/jnumed.108.055376.CrossRefPubMed

38.

Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM, et al. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol. 2013;88(5):400–5. https://doi.org/10.1002/ajh.23423.CrossRefPubMed

39.

Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Ann Oncol. 2009;20(2):309–18. https://doi.org/10.1093/annonc/mdn629.CrossRefPubMed

40.

Sun N, Zhao J, Qiao W, Wang T. Predictive value of interim PET/CT in DLBCL treated with R-CHOP: meta-analysis. Biomed Res Int. 2015;2015:648572. https://doi.org/10.1155/2015/648572.CrossRefPubMedPubMedCentral

41.

Marcatili S, Pichard A, Courteau A, Ladjohounlou R, Navarro-Teulon I, Repetto-Llamazares A, et al. Realistic multi-cellular dosimetry for (177)Lu-labelled antibodies: model and application. Phys Med Biol. 2016;61(19):6935–52. https://doi.org/10.1088/0031-9155/61/19/6935.CrossRefPubMed

42.

Stokke C, Blakkisrud J, Londalen A, Dahle J, Martinsen ACT, Holte H, et al. Pre-dosing with lilotomab prior to therapy with (177)Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-3964-9.

43.

Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma - novel and emerging therapies. Cancer Manag Res. 2013;5:251–69. https://doi.org/10.2147/CMAR.S34273.CrossRefPubMedPubMedCentral

Title: FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
Authors: Ayca Løndalen
Johan Blakkisrud
Mona-Elisabeth Revheim
Ulf Erik Madsbu
Jostein Dahle
Arne Kolstad
Caroline Stokke
Publication date: 01-06-2021
Publisher: Springer Berlin Heidelberg
Keywords: Radioimmunotherapy
Non-Hodgkin Lymphoma
Rituximab
Rituximab
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-020-05098-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of ¹⁷⁷Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 6/2021

Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer

Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy

Comparison of MRI, [18F]FDG PET/CT, and 99mTc-UBI 29-41 scintigraphy for postoperative spondylodiscitis—a prospective multicenter study

Whole-body parametric [18F]-FDG PET/CT improves interpretation of a distant lesion as venous embolus in a lung cancer patient

Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation

Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT